Generalizable features of pegRNA design for prime editing of inherited retinal diseases
Authors:
- Freya M. PattersonFPFreya M. Patterson
- Minh Thuan Nguyen TranMTMinh Thuan Nguyen Tran
- Thomas GuinanTGThomas Guinan
- Mohd Khairul Nizam Mohd KhalidMKMohd Khairul Nizam Mohd Khalid
- Rajendra KcRKRajendra Kc
- Kirsten A. FairfaxKFKirsten A. Fairfax
- Guei-Sheung LiuGLGuei-Sheung Liu
- Anthony L. CookACAnthony L. Cook
- Sandy S. HungSHSandy S. Hung
- Alex W. HewittAHAlex W. Hewitt
Open Access
- 9 November 2025
- journal article
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 47 (1) , 59-66
Abstract
The variety of ocular cell types involved in inherited retinal disease (IRD) necessitates the use of gene editing therapeutics which have generalizable components. In our study, we investigate the generalizable characteristics of non-engineered pegRNA design (PE2) for efficient, proof-in-principle gene correction of over 21 genes implicated in IRDs and associated syndromes. We use a single-transgene oligopool approach, comprising approximately 12,000 uniquely barcoded pegRNAs that target a synthetically integrated, 50 bp sequence motif, which faithfully recapitulate the disease context of their various counterpart IRDs. Using this approach, we perform a high throughput, pooled analysis of pegRNA characteristics across non- and ocular cell types to propose a cell-line agnostic set of pegRNA design guidelines. Briefly, we find that non-engineered pegRNA 3' extensions should mediate substitution-type edits and that the desired edit should be placed within five nucleotides upstream of the nick site induced by the Cas-endonuclease. Further, PBS and RTT lengths of at least 12 and 14 nucleotides, respectively, should be used and each non-engineered pegRNA 3' extension should obviate an initial templating cytosine nucleotide. We establish a set of recommendations for the generalizable design of the non-engineered pegRNA 3' extension for the correction of several IRDs, enabling overall simplification of design parameters for PE2-based systems.Keywords
Funding Information
- National Health & Medical Research Council (GNT2009079)
This publication has 28 references indexed in Scilit:
- Emerging trends in virus and virus-like particle gene therapy delivery to the brainMolecular Therapy Nucleic Acids, 2024
- Phage-assisted evolution and protein engineering yield compact, efficient prime editorsCell, 2023
- Prediction of efficiencies for diverse prime editing systems in multiple cell typesCell, 2023
- Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD geneMolecular Therapy Nucleic Acids, 2022
- An Intein-Mediated Split–nCas9 System for Base Editing in PlantsACS Synthetic Biology, 2022
- Enhanced prime editing systems by manipulating cellular determinants of editing outcomesCell, 2021
- A System for the Evolution of Protein–Protein Interaction InducersACS Synthetic Biology, 2021
- Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis PigmentosaMolecular Therapy, 2020
- Mapping the genomic landscape of inherited retinal disease genes prioritizes genes prone to coding and noncoding copy-number variationsGenetics in Medicine, 2018
- Solid lipid nanoparticles for retinal gene therapy: Transfection and intracellular trafficking in RPE cellsInternational Journal of Pharmaceutics, 2008